Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Guidelines
Haematology

AHCD 1995

Association of Hemophilia Clinic Directors of Canada

Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada

1995NationalCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Canada

Read the PDF Original at the sourceAsk Osler about this guideline

On this page

Read the guideline
Abstract
Source and rights

Read the guideline

Full guideline, as published1.4 MBOpen in a new tab Download

Abstract

To present current strategies for the assessment and comprehensive care of patients with hemophilia and von Willebrand's disease.

Hospital care, home care, single-provider care and multidisciplinary care.

Morbidity and quality of life associated with bleeding and treatment.

More in haematology

Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026Added 23 Jul 2026PDF
Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026Added 31 Jul 2026PodcastInfographic

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Relevant clinical studies and reports published from 1974 to 1994 were examined. A search was conducted of own reprint files, MEDLINE, citations in the articles reviewed and references provided by colleagues. In the MEDLINE search the following terms were used singly or in combination: "hemophilia," "von Willebrand's disease," "Factor VIII," "Factor IX," "von Willebrand factor," "diagnosis," "management," "home care," "comprehensive care," "inhibitor," "AIDS," "hepatitis," "life expectancy," "complications," "practice guidelines," "consensus statement" and "controlled trial." The in-depth review included only articles written in English from North America and Europe that were relevant to human disease and to a predetermined outline. The availability of treatment products in Canada was also considered.

Minimizing morbidity and maximizing functional status and quality of life were given a high value.

The optimal use of treatment procedures and home care offers patients the advantages of minimized disability, improved survival and financial benefit. It is also cost effective. Potential harm, including the risk of hepatitis B, hepatitis C and HIV infection, has now been minimized through viral inactivation of plasma-derived coagulation-factor concentrates and through the use of recombinant clotting factor concentrates and other non-plasma-derived hemostatic agents.

Patients with hemophilia and severe von Willebrand's disease should be followed in comprehensive care centres that offer expertise in the diagnosis, assessment and management of bleeding and complications and that can meet the educational and counselling needs of patients, family members and health care providers. Eligible patients should be enrolled in a home self-infusion program. Patients with hemophilia and von Willebrand's disease should wear or carry Medic Alert identification. They should be vaccinated against hepatitis B and attend for routine follow-up examinations. Laboratory testing should be carried out as required, and dental and surgical care should be undertaken in consultation with a hematologist.

These recommendations were reviewed and approved by the Association of Hemophilia Clinic Directors of Canada (AHCDC) and the Medical and Scientific Advisory Committee of the Canadian Hemophilia Society. No similar consensus statements or practice guidelines are available for comparison.

These recommendations were developed at the request of the Canadian Blood Agency, which funds the provision of all coagulation-factor concentrates for people with congenital bleeding disorders, and were developed and endorsed by the AHCDC and the Medical and Scientific Advisory Committee of the Canadian Hemophilia Society.

Source and rights

Published by CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1995. The PDF is shown as published and remains the work of its authors and publisher; the original is at the source linked here. Rights holders can ask us to remove a file at info@prognia.nl.

pmc.ncbi.nlm.nih.gov/articles/PMC1337937/

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Organisation: Association of Hemophilia Clinic Directors of Canada
Published: 1995
Applies to: 🇨🇦 Canada
Scope: National
Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
PubMed: 7796372
PubMed Central: PMC1337937
Added to Prognia: 24 July 2026

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene TherapyAmerican Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy · 2026Added 29 Jul 2026PodcastInfographic

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyELN-DAVID MRD Working Party · 2026Added 29 Jul 2026

An International Survey on the Assessment of Screening and Treatment of Thrombosis Complications in Pediatrics (ASTRO-Kids): communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisAmerican Society for Radiation Oncology · 2026Added 23 Jul 2026

Guidelines for the management of acute porphyria: recommendations from the International Porphyria NetworkEuropean Respiratory Society · 2026Added 23 Jul 2026

Standardization of Platelet Activation Tests for the Diagnosis of Heparin-Induced Thrombocytopenia: Communication from the ISTH-SSC Subcommittee on Immune-Mediated Platelet DisordersInternational Society on Thrombosis and Haemostasis · 2026Added 23 Jul 2026

Emergent Transfusion and Hemolytic Disease of the Fetus and Newborn Risk Mitigation in Females of Childbearing Potential with Life-Threatening Bleeding: A Clinical Practice GuidelineJournal of the American College of Surgeons · 2026Added 23 Jul 2026PDF

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel RecommendationsAmerican journal of hematology · 2026Added 18 Jul 2026PDF

LYSA 2026Large B-cell lymphoma: The LYSA pragmatic guidelinesThe LYSA · 2026Added 18 Jul 2026PDF

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025Cancers · 2026Added 18 Jul 2026PDF

ASH 2026American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsAmerican Society of Hematology · 2026Added 17 Jul 2026PDF